PJSC Energomashspetsstal (EMSS, Kramatorsk, Donetsk region), the owner of which is Russia’s Atomenergomash, has signed a new agreement with Steel Authority of India (SAIL) for delivery of 1,190 tonnes of rolled products. The press service of EMSS has reported that the agreement was signed following tender in July 2019. The value of the contract is not disclosed.
The rolls will be produced for a new hot-rolling mill 2250 of Rourkela Steel Plant (RSP).
According to the contract, the products should be sent to the customer by the second quarter of 2021.
The company’s press service said a successful fulfillment of this order would favor further cooperation with SAIL into other projects.
For a moment, SAIL’s RSP is also waiting for another delivery under the previous order from EMSS that is to be sent to the customer by the beginning of 2020.
Energomashspetsstal is the largest Ukrainian producer of special cast and forged products for individual and small-scale production for metallurgy, shipbuilding, energy (wind, steam, hydro, nuclear) and general engineering.
SAIL is top five biggest companies of India.
Secretary of the National Security and Defense Council of Ukraine Oleksandr Danyliuk held a meeting with Indian Ambassador Partha Satpathy on Wednesday, during which the parties discussed the state of cooperation in the field of security and defense and prospects for its further intensification. “Satpathy stressed the importance of Ukraine as a strategic partner of India in the field of military-technical cooperation, in particular, the production and supply by Ukraine of gas turbine engines for ships and joint projects in the field of aviation,” the press service of the NSDC reports.
Also, the Ambassador of India assured of the unchanged support for the sovereignty and territorial integrity of Ukraine.
According to Danyliuk, to enhance cooperation at the strategic level, the current exchange of information between Ukraine and India on security issues is relevant today.
Ukraine can join India, Israel, and Thailand and become another major platform for the rapidly growing industry of clinical trials of new drugs, James Peyer, managing partner of the U.S. biotechnology company Apollo Ventures, has said. “Clinical trials can be carried out (in Ukraine) with the same level of professionalism, with the same level of effectiveness as in the United States and Europe but without their high costs,” he said at the Ukraine House Davos health panel.
As reported earlier, bill No. 4074 on ensuring public access to the results of preclinical study and clinical trials of medicines was passed into law by the Ukrainian parliament in September 2018.
At present, about 200 clinical drug trials are underway in Ukraine. At the same time, in the past two years, the trend toward a decrease in the number of clinical trials has subsided.
Trade turnover between Ukraine and India in January-October 2018 amounted to $2.3 billion, of which $1.5 billion was the cost of sunflower oil, First Deputy Prime Minister, Minister of Economic Development and Trade Stepan Kubiv has said. “India ranks first in terms of exports of Ukrainian goods to the countries of the Asia-Pacific region and is the fifth largest buyer of Ukrainian products among countries in the world,” he wrote on Facebook.
The Ministry of Economic Development and Trade said on Twitter the Ukrainian delegation headed by Kubiv on January 11-13 is on a working visit to India to participate in the 25th international summit “New India: Rising to Global Occasions.”
India could expand a portfolio of generics exported to Ukraine thanks to medications that lost patent protection of innovative drugs, which will become available before 2020, President of the Indian Pharmaceutical Manufacturers’ Association (IPMA) Dr. Ramanan Unni Parambath Menon has told Interfax-Ukraine. “Exports of Indian pharmaceutical products will grow, and the portfolio of generic products that can be supplied to Ukraine will expand, since by 2020 branded drugs worth about $55 billion will lose patent protection,” he said on the sidelines of the annual business seminar “India – Global force in pharmaceutics – Reliable partner for Ukraine” held late November in Kyiv.
He said that at present, retail and hospital sales of Indian medicines account for more than UAH 2.633 billion per year, including UAH 334.3 million in the hospital segment. The share of branded generic production of Indian pharmaceutical companies is 59.4% of this segment. According to Dr. Menon, “generic products are market drivers.” “The share of generic drugs is growing in monetary terms and in kind. Products of Indian companies are more branded generics,” he said.
Currently, the top 10 Indian pharmaceutical companies on the Ukrainian market include five IPMA member companies – Dr. Reddys, Abryl Formulations, Organosyn Life Sciences, SUN Pharma, Macleods Pharmaceuticals; and two IPMA member companies are in the top 20 – Aurobindo Pharma and Hetero Labs.
In total, 365 Indian brands are currently represented in the Ukrainian pharmaceutical market.
The IPMA predicts that by the end of 2018, sales of Indian medicines in Ukraine will grow by 22.7% in hryvnias or 19.9% in U.S. dollars compared with 2017. At the same time, sales of Indian drugs in kind will increase by 2.5%.
The growth in sales of Indian pharmaceutical products in 2019 in monetary terms could be 18.1% in hryvnias or 9.5% in U.S. dollars, while maintaining the total supply volumes.
The Embassy of India in Kyiv, in association with Pharmaceuticals Export Promotion Council of India (PHARMEXCIL) and Indian Pharmaceuticals Manufacturers Association (IPMA), Ukraine is organizing the annual business seminar on pharmaceutical and herbal sectors “India- a Global Power in Pharmaceutical Sector: a Reliable Partner for Ukraine” on 30th November, 2018 in Kyiv to promote and display the potential of India in these sectors.
For more information, please send a request to the e-mail com.kyiv.india@gmail.com.
Accreditation for media representatives is obligatory under the following link: goo.gl/7cGuVS
